Summerset Group Holdings Limited

SNZ

Summerset Group Holdings Ltd. engages in the development and operation of retirement villages and aged care facilities. The firm is engaged in the design, construction, and operation of retirement villages and care centers. The company provides a range of living options and care services to over 8,000 residents. The company offers a choice of independent living options, including villas, townhouses, and serviced apartments. The company offers various facilities in its village, such as recreational bowling green, barbecue facilities, cafe, communal vegetable gardens, courtesy van, exercise room, hair salon, library, organized outings, and activities, piano, pool table, residents' bar, residents' workshop, swimming pool, and spa. The company has approximately 38 villages completed or in development in Aotea, Avonhead, Bell Block, Blenheim, Cambridge, Casebrook, Cranbourne North, Dunedin, Ellerslie, and others. Its portfolio covers over 7,371 total units, including 6,087 retirement units and 1,284 care units.

SOCO Corporation Ltd

SOC

SOCO Corp. Ltd. engages in the provision of information technology (IT) consultancy services. The company is headquartered in Brisbane, Queensland and currently employs 78 full-time employees. The company went IPO on 2022-12-23. The firm specializes in the delivery of cloud solutions, business applications and integration projects with a focus on Microsoft solutions. The company serves various industries, including the federal government, state government, health care, construction, energy, and education. The Company’s technologies include Dynamics 365, Business Central, SharePoint, Microsoft Teams, Power Platform, Power Automate, Power Apps, Power BI, Office 365, Nintex, Dynamics 365 Sales, Dynamics 365 Marketing, Dynamics 365 Customer Service, Dynamics 365 Field Service, Dynamics 365 Remote Assist, and Managed D365 + M365 Support. Its solution areas include Intranets, Microsoft Licensing, Business Automation, Information Management, Digital Strategy + Architecture, Cloud Advisory Service, Enterprise Resource Planning, SharePoint Health Checks, Adoption + Engagement Expertise, and Managed D365 + M365 Support.

Sensen Networks Limited

SNS

SenSen Networks Ltd. engages in the development, commercialization, and supply of data-driven business process enhancement solutions. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2007-05-31. The principal activities of the Company include developing and selling SenDISA platform-based products and services into smart city and retail markets across three market segments: Smart Cities, Casinos, and Retail. Smart Cities include civic compliance, traffic data and law enforcement solutions to city councils, national parks, road authorities and transit agencies across the globe. Casinos include delivering actionable insights about casino table game occupancy, hands per hour, bet type and value for every bet placed on the gaming floor. Retail provides anti-theft and debt recovery services to fuel retailers. The Company’s geographical segments include Australia and New Zealand, North America (comprising USA and Canada), and Asia. SenDISA’s Live Awareness automates processes and ensures other decisions can be made more quickly and accurately.

Syntara Limited

SNT

Syntara Ltd. is a pharmaceutical research company, which engages in the development and commercialization of healthcare products for fibrotic and inflammatory diseases. The company is headquartered in Frenchs Forest, New South Wales. The company went IPO on 2003-11-10. The Company’s highly productive drug discovery engine is driven by its expertise in amine oxidase inhibitors. Its lead candidate, PXS-5505, is used for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The firm is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its PXS-4728 is a SSAO/MAOB inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis, and cardiac fibrosis. The company has developed two respiratory products: Bronchitol, for cystic fibrosis, and Aridol, a lung function test.